Therapeutic targets of triple‐negative breast cancer: a review | Zendy

Jamdade Vinayak S | Zendy; Sethi Nikunj | Zendy; Mundhe Nitin A | Zendy; Kumar Parveen | Zendy; Lahkar Mangala | Zendy; Sinha Neeraj | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Therapeutic targets of triple‐negative breast cancer: a review

Author(s) -

Jamdade Vinayak S,

Sethi Nikunj,

Mundhe Nitin A,

Kumar Parveen,

Lahkar Mangala,

Sinha Neeraj

Publication year - 2015

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.13211

Subject(s) - triple negative breast cancer , breast cancer , medicine , cancer , oncology

Breast cancer ( BC ) is the second most common cause of cancer deaths. Triple‐negative breast cancer ( TNBC ) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC . This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC . This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, W nt/β‐catenin and Hedgehog pathways, in addition to EGFR , PARP1 , mTOR , TGF ‐β and angiogenesis inhibitors.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research